Wave Life Sciences Ltd.

NasdaqGM:WVE Rapport sur les actions

Capitalisation boursière : US$688.6m

La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !

Wave Life Sciences Croissance future

Future contrôle des critères 2/6

Wave Life Sciences devrait augmenter ses bénéfices et ses revenus de 13.3% et de 30.9% par an respectivement, tandis que le BPA devrait croître de croître de 19.5% par an.

Informations clés

13.3%

Taux de croissance des bénéfices

19.5%

Taux de croissance du BPA

Pharmaceuticals croissance des bénéfices23.6%
Taux de croissance des recettes30.9%
Rendement futur des capitaux propresn/a
Couverture par les analystes

Good

Dernière mise à jour09 Aug 2024

Mises à jour récentes de la croissance future

Recent updates

We're Keeping An Eye On Wave Life Sciences' (NASDAQ:WVE) Cash Burn Rate

Aug 05
We're Keeping An Eye On Wave Life Sciences' (NASDAQ:WVE) Cash Burn Rate

Pinning Down Wave Life Sciences Ltd.'s (NASDAQ:WVE) P/S Is Difficult Right Now

Jun 25
Pinning Down Wave Life Sciences Ltd.'s (NASDAQ:WVE) P/S Is Difficult Right Now

We Think Wave Life Sciences (NASDAQ:WVE) Can Easily Afford To Drive Business Growth

Apr 09
We Think Wave Life Sciences (NASDAQ:WVE) Can Easily Afford To Drive Business Growth

Wave Life Sciences' Weighty Ambition: Carving Out Obesity Niche

Mar 09

Wave Life Sciences Ltd.'s (NASDAQ:WVE) 30% Price Boost Is Out Of Tune With Revenues

Mar 03
Wave Life Sciences Ltd.'s (NASDAQ:WVE) 30% Price Boost Is Out Of Tune With Revenues

We're Interested To See How Wave Life Sciences (NASDAQ:WVE) Uses Its Cash Hoard To Grow

Sep 13
We're Interested To See How Wave Life Sciences (NASDAQ:WVE) Uses Its Cash Hoard To Grow

Wave Life Sciences Ltd. (NASDAQ:WVE) Analysts Just Cut Their EPS Forecasts Substantially

May 08
Wave Life Sciences Ltd. (NASDAQ:WVE) Analysts Just Cut Their EPS Forecasts Substantially

Here's Why Wave Life Sciences (NASDAQ:WVE) Must Use Its Cash Wisely

Mar 30
Here's Why Wave Life Sciences (NASDAQ:WVE) Must Use Its Cash Wisely

Are Investors Undervaluing Wave Life Sciences Ltd. (NASDAQ:WVE) By 47%?

Jan 20
Are Investors Undervaluing Wave Life Sciences Ltd. (NASDAQ:WVE) By 47%?

Some Analysts Just Cut Their Wave Life Sciences Ltd. (NASDAQ:WVE) Estimates

Nov 11
Some Analysts Just Cut Their Wave Life Sciences Ltd. (NASDAQ:WVE) Estimates

Is Wave Life Sciences (NASDAQ:WVE) In A Good Position To Deliver On Growth Plans?

Aug 12
Is Wave Life Sciences (NASDAQ:WVE) In A Good Position To Deliver On Growth Plans?

Wave Life Sciences Q2 2022 Earnings Preview

Aug 10

Will Wave Life Sciences (NASDAQ:WVE) Spend Its Cash Wisely?

Apr 21
Will Wave Life Sciences (NASDAQ:WVE) Spend Its Cash Wisely?

Is Wave Life Sciences (NASDAQ:WVE) In A Good Position To Invest In Growth?

Jan 11
Is Wave Life Sciences (NASDAQ:WVE) In A Good Position To Invest In Growth?

We Think Wave Life Sciences (NASDAQ:WVE) Needs To Drive Business Growth Carefully

Sep 24
We Think Wave Life Sciences (NASDAQ:WVE) Needs To Drive Business Growth Carefully

What Does The Future Hold For Wave Life Sciences Ltd. (NASDAQ:WVE)? These Analysts Have Been Cutting Their Estimates

Aug 07
What Does The Future Hold For Wave Life Sciences Ltd. (NASDAQ:WVE)? These Analysts Have Been Cutting Their Estimates

Wave Life Sciences posts proof-of-concept data from genetic disorder study

Jun 02

Wave Life Sciences Ltd. (NASDAQ:WVE) Analysts Just Slashed This Year's Estimates

May 15
Wave Life Sciences Ltd. (NASDAQ:WVE) Analysts Just Slashed This Year's Estimates

Things Look Grim For Wave Life Sciences Ltd. (NASDAQ:WVE) After Today's Downgrade

Apr 02
Things Look Grim For Wave Life Sciences Ltd. (NASDAQ:WVE) After Today's Downgrade

Prévisions de croissance des bénéfices et des revenus

NasdaqGM:WVE - Estimations futures des analystes et données financières antérieures (USD Millions )
DateRecettesLes revenusFlux de trésorerie disponibleCash from OpMoy. Nombre d'analystes
12/31/202689-138-188-1507
12/31/202556-156-147-1358
12/31/202462-138-138-1507
6/30/2024111-73-130-129N/A
3/31/2024113-62-139-138N/A
12/31/2023113-58-21-19N/A
9/30/202385-85-21-20N/A
6/30/202337-131-12-11N/A
3/31/202315-151-4-2N/A
12/31/20224-162-129-128N/A
9/30/20224-153-103-101N/A
6/30/202240-120-105-104N/A
3/31/202243-118-85-84N/A
12/31/202141-122-90-89N/A
9/30/202149-116-114-113N/A
6/30/202116-143-106-105N/A
3/31/202116-145-135-134N/A
12/31/202020-150-117-116N/A
9/30/202013-178-148-146N/A
6/30/202013-196-172-169N/A
3/31/202017-197-168-164N/A
12/31/201916-194-192-188N/A
9/30/201917-175-166-160N/A
6/30/201919-162-154-145N/A
3/31/201916-156-50-41N/A
12/31/201814-147-33-23N/A
9/30/201812-140-23-13N/A
6/30/20189-127-20-7N/A
3/31/20185-116N/A-99N/A
12/31/20174-102N/A-84N/A
9/30/20173-90N/A-74N/A
6/30/20173-82N/A-63N/A
3/31/20172-69N/A-42N/A
12/31/20161-56N/A-32N/A
9/30/20161-44N/A-25N/A
6/30/20160-31N/A-16N/A
3/31/20160-24N/A-18N/A
12/31/20150-19N/A-13N/A
9/30/20150-14N/A-7N/A
6/30/20150-10N/A-5N/A
3/31/20150-8N/A-5N/A
12/31/2014N/A-5N/A-4N/A

Prévisions de croissance des analystes

Taux de revenus par rapport au taux d'épargne: WVE devrait rester non rentable au cours des 3 prochaines années.

Bénéfices vs marché: WVE devrait rester non rentable au cours des 3 prochaines années.

Croissance élevée des bénéfices: WVE devrait rester non rentable au cours des 3 prochaines années.

Chiffre d'affaires vs marché: Le chiffre d'affaires de WVE ( 30.9% par an) devrait croître plus rapidement que le marché US ( 8.8% par an).

Croissance élevée des revenus: Le chiffre d'affaires de WVE ( 30.9% par an) devrait croître plus rapidement que 20% par an.


Prévisions de croissance du bénéfice par action


Rendement futur des capitaux propres

ROE futur: Données insuffisantes pour déterminer si le retour sur capitaux propres de WVE devrait être élevé dans 3 ans


Découvrir les entreprises en croissance